A 72.2% confirmed objective response rate in first-line RAS-mutated metastatic colorectal cancer is not a number Cardiff Oncology buried in a footnote — it is the entire argument for why a single-arm Phase 2 signal became an FDA-endorsed Phase 3 program. The comparison matters: the combined standard-of-care arms in CRDF-004 landed at 43.2% ORR, and the progression-free survival hazard ratio for the onvansertib 30 mg plus FOLFIRI/bevacizumab arm versus control came in at 0.37 with a p-value below 0.05. For a PLK1 inhibitor in a population defined by the mutation that has historically defied targeted therapy, those figures demand scrutiny rather than celebration.
The End-of-Phase 2 FDA meeting resolved two critical design questions: dose and backbone chemotherapy. Cardiff locked in 30 mg onvansertib with FOLFIRI/bevacizumab, sidelining the FOLFOX combination that also ran in Phase 2. That selection is consequential. FOLFOX and FOLFIRI are not interchangeable in clinical practice — patients often sequence through one before the other — so anchoring the registrational trial to FOLFIRI/bev defines the exact line of therapy being targeted and shapes how oncologists will read an eventual approval label. The full Phase 3 design, including enrollment size, primary endpoint, and stratification factors, remains undisclosed until mid-2026, which means the ASCO rapid oral presentation on May 29 through June 2 carries unusual weight: updated CRDF-004 data will be the only granular look at durability and subgroup consistency before the Phase 3 blueprint drops.
The financial picture imposes a hard constraint on all of this. Cardiff held $46.1 million in cash at March 31, burning approximately $12.3 million in operating cash per quarter. That runway extends into Q1 2027 — enough to present data and publish a Phase 3 design, but not enough to initiate meaningful enrollment without additional capital. R&D expenses actually fell $3.7 million year-over-year, largely from reduced clinical trial spending, which is the right direction for a company between phases but signals that Phase 3 startup costs have not yet hit the income statement. Preclinical work combining onvansertib with trastuzumab deruxtecan in HER2-low breast cancer adds pipeline optionality, but it is noise relative to the core execution risk.
The number to track at ASCO is median PFS in the 30 mg FOLFIRI/bev arm with mature follow-up — not the hazard ratio, which the January readout already provided, but the absolute months of progression-free survival that will anchor the Phase 3 primary endpoint negotiation and determine whether the efficacy signal holds as the dataset ages.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
